Moleculin Biotech, Inc. (MBRX)
Develops experimental cancer drugs targeting tumors through immune modulation and energy deprivation.
$2.19+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-86.8%
The outlook
MBRX trades at $2.19, well below both its 50- and 200-day moving averages and near its 52-week low. Analyst coverage is sparse, but the average price target sits roughly 9× the current price, reflecting high dispersion in views. The overall sentiment leans bearish despite the optimistic target spread.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +859% vs current price
Analyst price target
~12-month · 3 analysts$21.00average target+858.9% vs now
Now $2.19
Low $10.00High $31.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$15.5M
52-wk high
$18.75
52-wk low
$1.79
50-day avg
$2.51
200-day avg
$4.68
Trailing P/E
—